Articles tagged with Radiation Therapy
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A new study found that hypofractionation does not increase complications for patients with breast cancer who undergo mastectomy and plan breast reconstruction. The trial enrolled 898 patients and showed that reducing treatment time by nearly half is safe and effective, saving patients time and money.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
Natural Killer (NK) cell-based therapies have shown promise in preclinical and clinical studies for treating Acute Myeloid Leukemia (AML), offering a potential cure with minimal prior antigen sensitization. However, the dysfunction of NK cells in AML patients poses a significant challenge that must be overcome to unlock their full ther...
A survey found that spiritual beliefs and distrust of clinical research contribute to Black patients' hesitation to enroll in cancer trials. Despite trusting their medical teams, some patients express concerns about the purpose of research and its potential impact on their health and community.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Leading researchers from Penn Medicine will showcase clinical trial results and new data on FLASH radiation therapy. The institution is one of the world’s leading academic medical centers, with a proud history of groundbreaking discoveries and innovations.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Recent advances in radiation therapy have improved breast cancer outcomes with reduced side effects. Researchers at MD Anderson have demonstrated the benefits of hypofractionation in reducing lymphedema risk and improving treatment tolerance.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
Researchers have discovered copper-based nanocapsules that can trigger cuproptosis in tumor cells, overcoming acquired radiation resistance and improving the effectiveness of radiotherapy. The nanocapsules also activate an abscopal effect, inducing immunogenic cell death and stimulating antitumor immunity.
Researchers integrated personalized daily adjustments into proton therapy, ensuring more precise treatment and reduced radiation exposure. The new workflow, developed by PSI researchers, involves low-dose CT scans before each irradiation and adapts the treatment plan to the patient's current anatomy.
Researchers have developed a novel platform for testing radiation therapy effects on brain cells, providing insights into how the brain reacts to cancer treatment. The study aims to improve treatment strategies by understanding the impact of radiation on neural circuits, ultimately leading to personalized care for patients.
A new study published in The BMJ found that shorter-course radiation therapy is safer and more convenient for breast cancer patients than conventional schedules. Moderate hypofractionation reduced the risk of acute radiation dermatitis by 46% compared to conventional fractionation, while also improving cosmesis and quality of life.
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.
A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.
A 30-year study suggests that radiotherapy can prevent breast cancer recurrence in the same location for up to 10 years after surgery, but survival rates remain similar. The study found fewer deaths from breast cancer among those who received radiotherapy compared to those who did not.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
Researchers have developed novel X-ray-sensitizers that can efficiently generate singlet oxygen for targeted cancer therapy using low-dose X-rays. This breakthrough could lead to a more effective and patient-friendly alternative to current radiotherapy methods, potentially reducing the risk of adverse effects.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Pre-clinical trials show that targeted alpha radiation therapy can increase survival rates by up to 36.4% and has minimal adverse effects for patients. Researchers hope this new approach could improve current average survival rates beyond 18 months.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant to advance personalized cancer therapy for prostate cancer patients. They aim to predict and prevent long-term side effects from radiation treatment, improving quality of life for men diagnosed with the disease.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
Researchers have made significant progress in understanding the one-neutron stripping process in lithium-6 and bismuth-209 reactions. The study reveals that this process yields results comparable to fusion reactions, especially at energy regions near nuclear barriers.
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
A Phase III trial led by the University of Texas M. D. Anderson Cancer Center found proton therapy to be non-inferior to traditional radiation therapy in treating head and neck cancer. The study revealed a significant reduction in malnutrition and feeding-tube dependency with proton therapy.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
Researchers at MUSC Hollings Cancer Center discover polyploid giant cancer cells can lead to disease recurrence after chemotherapy or radiotherapy. They found that targeting these 'monster cells' could prevent tumor relapse, and potential therapies like tamoxifen and statins may also be effective.
The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.
Researchers have identified collagen features as valuable biomarkers for evaluating melanoma immunotherapy response. Single-fiber characteristics were found to be more sensitive to treatment-induced changes than bulk collagen features, offering insights into collagen remodeling over time.
Researchers aim to develop FLASH radiotherapy for treating skin cancer, rectal cancer and sarcomas with fewer side effects and less damage to healthy tissues. The project focuses on calibrating equipment and conducting lab studies to apply the technique safely and effectively in clinical settings.
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
The HZDR team has made a significant advance in laser plasma acceleration, achieving energies of up to 150 MeV for protons. This breakthrough opens up promising applications in medicine and materials science, including new radiobiological concepts for tumor treatment.
Men with prostate cancer who listened to mindfulness audio recordings during radiation therapy experienced significant reductions in fatigue, sleep problems, anxiety, and depressive symptoms. The study found that the mindfulness intervention was more effective than listening to relaxing music during treatment.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Researchers from Penn Medicine will share data on the latest advances in cancer science and medicine, including novel targets in the tumor microenvironment and the influence of the microbiome on cancer therapy. The presentation is part of the American Association for Cancer Research (AACR) Annual Meeting 2024.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Researchers found that young breast cancer patients who received a low-dose radiotherapy boost had a lower risk of local recurrence after 10 years, with only 4.4% experiencing recurrence. In contrast, high-dose boosts resulted in fewer recurrences but also more severe fibrosis and cosmetic issues.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
A high-impact study demonstrates the safety and efficacy of relugolix in conjunction with radiation therapy for localized and advanced prostate cancer, achieving rapid castration and maintaining low testosterone levels. The study also shows no difference between relugolix and leuprolide in time to castration-resistant prostate cancer.
A new study reveals that MAGE family proteins bind to RAD18 using a groove, preventing its degradation and contributing to cancer progression. The findings also suggest that blocking this interaction could lead to re-sensitization of cancer cells to chemotherapy and radiotherapy.
Seven high-impact studies will be showcased, exploring novel therapies and improving treatment outcomes for patients with head and neck squamous cell carcinoma. These findings highlight advancements in immunotherapy, risk-directed adjuvant therapy, and FDG-PET-based selective de-escalation of radiotherapy.
Two new studies reveal that UK cancer patients face long waits for chemotherapy and radiotherapy, leading to poorer outcomes. The research highlights the need for a strategic approach to addressing treatment variation and improving cancer services in the UK.
Researchers at UT Health Science Center, in collaboration with Oak Ridge National Laboratory and the University of Tennessee, Knoxville, will develop new radiopharmaceutical therapies to treat cancer. The team aims to advance precision cancer treatment using targeted alpha-emitting radioisotope constructs.
A new computer model of a human lung is being used to simulate the interaction of radiation with lung tissue at a cellular level. This could lead to more targeted treatments for cancer and reduce damage caused by radiotherapy.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
Researchers developed a molecular predictor of radiation response using cell line data and machine learning-based approaches, capturing a wider range of biological processes. The new gene signature has the potential to aid decision-making, personalize treatments, and improve outcomes for various types of cancers.
Researchers explore the use of traditional Chinese medicine (TCM) compounds for treating non-alcoholic fatty liver disease (NAFLD) and improving sensitivity to radiation therapy for lung cancer. TCM compounds, such as oridonin and ginsenoside Rg5, have demonstrated anti-inflammatory effects and radiosensitizing properties.